Vakharia is assistant professor of dermatology at Northwestern University Feinberg School of Medicine in Chicago. The information here represents his knowledge and experience as a medical professional ...

Despite the approval of dupilumab (Dupixent) in September 2022, there is an ongoing dearth of clinically effective treatments for prurigo nodularis, prompting the present investigation of the ...

Please provide your email address to receive an email when new articles are posted on . Prurigo nodularis, a chronic debilitating inflammatory skin disease that causes extreme quality of life ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SWX:GALD) today announced that full results from the phase III OLYMPIA 1 trial, a 24-week study which evaluated the efficacy and safety of nemolizumab ...

Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by firm, itchy, and often painful bumps (nodules) on the skin. It typically begins with intense itchiness, which can be ...

Paris and Tarrytown, N.Y. September 28, 2022. The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adult patients with prurigo nodularis. With this ...

Prurigo nodularis is an extremely itchy skin condition. It causes a rash that often includes hard lumps called nodules. You might also hear it called nodular prurigo. Doctors don’t know exactly what ...

Nemolizumab, which targets the interleukin-31 pathway, rapidly improves itch and sleep in people with atopic dermatitis and ...

Prurigo nodularis is a disabling chronic skin condition characterized by severely itchy, crusty, firm papules and nodules that often occur on the arms and legs, but can appear diffusely on the body.

WASHINGTON (Dec. 13, 2018) -- Prurigo nodularis is a disabling chronic skin condition characterized by severely itchy, crusty, firm papules and nodules that often occur on the arms and legs, but can ...

About 75,000 adults in the U.S. living with prurigo nodularis are most in need of new treatment options. TARRYTOWN, N.Y. and PARIS, Sept. 28, 2022/ PRNewswire/-- Regeneron Pharmaceuticals, Inc. and ...